A Phase 1b Study of SGN-75 in Combination With Everolimus in Patients With Renal Cell Carcinoma

ClinicalTrials.gov ID: NCT01677390

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT01677390. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 15, 2026, 9:58 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1b, Open-label, Dose-escalation Study to Evaluate the Safety and Tolerability of SGN-75 in Combination With Everolimus in Patients With CD70-positive Metastatic Renal Cell Carcinoma

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a phase 1, open-label, dose-escalation clinical trial to evaluate the safety of SGN-75 in combination with everolimus in patients with CD70-positive metastatic renal cell carcinoma.

Study identification

NCT ID: NCT01677390
Recruitment status: Terminated
Study type: Interventional
Phase: Phase 1
Lead sponsor: Seagen Inc.; Industry
Enrollment: 4 participants

Conditions and interventions

Conditions

Renal Cell Carcinoma

Interventions

SGN-75 Drug
everolimus Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Aug 2012 (Type not available)
Primary completion: Dec 2013 (Actual)
Completion: Dec 2013 (Actual)
Last update posted: Jan 28, 2014

2012 – 2013

United States locations

U.S. sites: 8
U.S. states: 8
U.S. cities: 8

Facility	City	State	ZIP	Site status
Stanford Cancer Center	Stanford	California	94305	—
Rocky Mountain Cancer Centers - Midtown	Denver	Colorado	80218	—
Karmanos Cancer Institute / Wayne State University	Detroit	Michigan	48201	—
Memorial Sloan Kettering Cancer Center	New York	New York	10065	—
UNC Lineberger Comprehensive Cancer Center / University of North Carolina	Chapel Hill	North Carolina	27599	—
Miriam Hospital, The	Providence	Rhode Island	02906	—
Sarah Cannon Research Institute	Nashville	Tennessee	37203	—
Seattle Cancer Care Alliance / University of Washington	Seattle	Washington	98109-1023	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT01677390, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jan 28, 2014 · Synced Nov 15, 2026